Crossmark

Isorhamnetin ameliorates active ulcerative colitis potentially involving the Nrf2-PTGS2 axis: an integrative study from clinical evidence mining to in vivo validation

Crossref DOI link: https://doi.org/10.1007/s00210-026-05737-4

Published Online: 2026-07-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fan, Zhenjia

Zhao, Luqing

Ding, Ning

Wang, Yichong

Li, Danyan

Zhang, Shengsheng
License Information

Text and Data Mining valid from 2026-07-25

Version of Record valid from 2026-07-25
More Information

Article History

Received: 8 May 2026

Accepted: 15 July 2026

First Online: 25 July 2026

Declarations

Ethics approval: This study was approved by the Animal Ethics Committee of the Beijing Institute of Chinese Medicine (No. BJTCM-M-2025–11-05).

Competing interests: The authors declare no competing interests.

Clinical trial number: Not applicable.

Document is current

Any future updates will be listed below